{"title":"脯氨酰寡肽酶抑制剂结合的结构可视化。","authors":"Katarzyna Walczewska-Szewc, Jakub Rydzewski","doi":"10.1063/5.0226428","DOIUrl":null,"url":null,"abstract":"<p><p>The association and dissociation of proteins and ligands are crucial in biophysics for potential drug development [Baron and McCammon, Annu. Rev. Phys. Chem. <b>64</b>, 151-175 (2013)]. However, identifying and characterizing the reaction pathways for these rare events has been a long-standing challenge. Molecular dynamics (MD) simulations are limited in exploring biophysical processes on experimental timescales, so ligand transport processes through complex transient tunnels formed by proteins during dynamics are often simulated using enhanced sampling MD [Rydzewski and Nowak, Phys. Life Rev. <b>22-23</b>, 58-74 (2017)]. Erroneously identified ligand binding pathways can affect thermodynamic and kinetic characteristics calculated from MD trajectories. A system that has the potential to be a therapeutic target for neurodegenerative diseases is prolyl oligopeptidase (PREP). This is due to its involvement in promoting protein aggregation and disrupting cellular function through affecting protein-protein interactions (PPI). The recent discovery of a new type of PREP inhibitor that targets PPI raises important questions about the diversity of ligand binding pathways in PREP and their impact on protein dynamics [Pätsi <i>et al.</i>, J. Med. Chem. <b>67</b>, 5421-5436 (2024); Kilpeläinen <i>et al.</i>, J. Med. Chem. <b>66</b>, 7475-7496 (2023); and Walczewska-Szewc <i>et al.</i>, Phys. Chem. Chem. Phys. <b>24</b>, 4366-4373 (2022)]. In this article, using results from enhanced sampling MD, we visually present how the binding process in PREP depends on subtle changes in inhibitors, which could be crucial in treating neurodegenerative disorders.</p>","PeriodicalId":72405,"journal":{"name":"Biophysics reviews","volume":"5 3","pages":"032105"},"PeriodicalIF":3.4000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343612/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structural visualization of inhibitor binding in prolyl oligopeptidase.\",\"authors\":\"Katarzyna Walczewska-Szewc, Jakub Rydzewski\",\"doi\":\"10.1063/5.0226428\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The association and dissociation of proteins and ligands are crucial in biophysics for potential drug development [Baron and McCammon, Annu. Rev. Phys. Chem. <b>64</b>, 151-175 (2013)]. However, identifying and characterizing the reaction pathways for these rare events has been a long-standing challenge. Molecular dynamics (MD) simulations are limited in exploring biophysical processes on experimental timescales, so ligand transport processes through complex transient tunnels formed by proteins during dynamics are often simulated using enhanced sampling MD [Rydzewski and Nowak, Phys. Life Rev. <b>22-23</b>, 58-74 (2017)]. Erroneously identified ligand binding pathways can affect thermodynamic and kinetic characteristics calculated from MD trajectories. A system that has the potential to be a therapeutic target for neurodegenerative diseases is prolyl oligopeptidase (PREP). This is due to its involvement in promoting protein aggregation and disrupting cellular function through affecting protein-protein interactions (PPI). The recent discovery of a new type of PREP inhibitor that targets PPI raises important questions about the diversity of ligand binding pathways in PREP and their impact on protein dynamics [Pätsi <i>et al.</i>, J. Med. Chem. <b>67</b>, 5421-5436 (2024); Kilpeläinen <i>et al.</i>, J. Med. Chem. <b>66</b>, 7475-7496 (2023); and Walczewska-Szewc <i>et al.</i>, Phys. Chem. Chem. Phys. <b>24</b>, 4366-4373 (2022)]. In this article, using results from enhanced sampling MD, we visually present how the binding process in PREP depends on subtle changes in inhibitors, which could be crucial in treating neurodegenerative disorders.</p>\",\"PeriodicalId\":72405,\"journal\":{\"name\":\"Biophysics reviews\",\"volume\":\"5 3\",\"pages\":\"032105\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343612/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biophysics reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1063/5.0226428\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"BIOPHYSICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biophysics reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1063/5.0226428","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
摘要
蛋白质和配体的结合与解离在生物物理学中对潜在药物开发至关重要[Baron 和 McCammon,Annu. Rev. Phys. Chem. 64, 151-175 (2013)]。然而,识别和描述这些罕见事件的反应途径一直是一项长期挑战。分子动力学(MD)模拟在探索实验时间尺度上的生物物理过程时受到了限制,因此配体通过蛋白质在动力学过程中形成的复杂瞬时隧道的运输过程通常采用增强采样 MD 模拟[Rydzewski and Nowak, Phys. Life Rev. 22-23, 58-74 (2017)]。错误识别的配体结合路径会影响 MD 轨迹计算出的热力学和动力学特征。有可能成为神经退行性疾病治疗靶点的一个系统是脯氨酰寡肽酶(PREP)。这是因为它参与促进蛋白质聚集,并通过影响蛋白质-蛋白质相互作用(PPI)破坏细胞功能。最近发现的一种针对 PPI 的新型 PREP 抑制剂,提出了 PREP 中配体结合途径多样性及其对蛋白质动态影响的重要问题 [Pätsi 等人,J. Med.Chem.67, 5421-5436 (2024); Kilpeläinen et al., J. Med.Chem.66,7475-7496 (2023);以及 Walczewska-Szewc 等人,Phys.Chem.24, 4366-4373 (2022)]。在本文中,我们利用增强采样 MD 的结果,直观地展示了 PREP 中的结合过程如何取决于抑制剂的微妙变化,这可能对治疗神经退行性疾病至关重要。
Structural visualization of inhibitor binding in prolyl oligopeptidase.
The association and dissociation of proteins and ligands are crucial in biophysics for potential drug development [Baron and McCammon, Annu. Rev. Phys. Chem. 64, 151-175 (2013)]. However, identifying and characterizing the reaction pathways for these rare events has been a long-standing challenge. Molecular dynamics (MD) simulations are limited in exploring biophysical processes on experimental timescales, so ligand transport processes through complex transient tunnels formed by proteins during dynamics are often simulated using enhanced sampling MD [Rydzewski and Nowak, Phys. Life Rev. 22-23, 58-74 (2017)]. Erroneously identified ligand binding pathways can affect thermodynamic and kinetic characteristics calculated from MD trajectories. A system that has the potential to be a therapeutic target for neurodegenerative diseases is prolyl oligopeptidase (PREP). This is due to its involvement in promoting protein aggregation and disrupting cellular function through affecting protein-protein interactions (PPI). The recent discovery of a new type of PREP inhibitor that targets PPI raises important questions about the diversity of ligand binding pathways in PREP and their impact on protein dynamics [Pätsi et al., J. Med. Chem. 67, 5421-5436 (2024); Kilpeläinen et al., J. Med. Chem. 66, 7475-7496 (2023); and Walczewska-Szewc et al., Phys. Chem. Chem. Phys. 24, 4366-4373 (2022)]. In this article, using results from enhanced sampling MD, we visually present how the binding process in PREP depends on subtle changes in inhibitors, which could be crucial in treating neurodegenerative disorders.